Alvotech Initiates Confirmatory Patient Study for AVT05, a Proposed Biosimilar for Simponi® and Simponi Aria®GlobeNewsWire • 05/04/23
ALVO, ALVOW INVESTOR NEWS: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Alvotech Investors With Losses in Excess of $100K to Inquire About Securities Class Action Investigation – ALVOWBusiness Wire • 05/03/23
Alvotech to Report First Quarter 2023 Financial Results and Recent Business Highlights on May 18, 2023 and Host Conference Call on May 19, 2023 at 8:00 am ETGlobeNewsWire • 05/03/23
ALVOTECH ALERT: Bragar Eagel & Squire, P.C. is Investigating Alvotech on Behalf of Alvotech Stockholders and Encourages Investors to Contact the FirmBusiness Wire • 04/20/23
Sarah Tanksley Joins Board of Directors for Alvotech hf. and Sandra Casaca Appointed Chief Quality OfficerGlobeNewsWire • 04/19/23
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Alvotech and Encourages Investors with Losses to Contact the FirmBusiness Wire • 04/19/23
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Alvotech (ALVO) on Behalf of InvestorsBusiness Wire • 04/19/23
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Alvotech (ALVO) on Behalf of InvestorsBusiness Wire • 04/18/23
The Law Offices of Frank R. Cruz Announces Investigation of Alvotech (ALVO) on Behalf of InvestorsBusiness Wire • 04/18/23
Alvotech (ALVO) Declines on CRL for Humira's Biosimilar CandidateZacks Investment Research • 04/14/23
Alvotech to Present Clinical Study Data for AVT04, a Proposed Biosimilar to Stelara®, at 2023 American Academy of Dermatology (AAD) Annual MeetingGlobeNewsWire • 03/17/23
Alvotech Reports Financial Results for Full Year 2022 and Provides Business UpdateGlobeNewsWire • 03/01/23
Alvotech Announces Webcast of 2022 Full Year Financial Results at 8:00 am ET on March 2, 2023GlobeNewsWire • 02/28/23
Updated market making agreement with Landsbankinn for Alvotech shares trading on the Nasdaq Iceland marketGlobeNewsWire • 02/14/23
EMA Confirms Acceptance of Application for AVT04, a Proposed Biosimilar to Stelara® (ustekinumab)GlobeNewsWire • 02/09/23
Alvotech enters into commercialization agreement with Advanz Pharma for proposed biosimilar to Xolair® (omalizumab)GlobeNewsWire • 02/06/23
Alvotech Enters Into Commercialization Agreement With Advanz Pharma for Proposed Biosimilar to Xolair® (Omalizumab)GlobeNewsWire • 02/06/23
Alvotech and Bioventure Announce Approval of AVT02 (adalimumab) as Simlandi in Saudi ArabiaGlobeNewsWire • 01/24/23